GSK plc GSK announced that the U.S. Centers for Disease Control and Prevention’s (“CDC”) Advisory Committee on Immunization ...

GSK (GSK) announced that the US CDC’s Advisory Committee on Immunization Practices has voted to recommend use of Penmvevy as part of the ...

A vaccine against meningococcal disease or any other disease works by generating an immune response in the body against some kind of pathogen—a virus, bacterium, or some other agent that causes ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy ... causing serogroups of Neisseria meningitidis (A, B, C, W and Y), covering five of the six serogroups that ...

Both Novartis and Pfizer have serogroup B vaccines in development. Globally, infants are at the highest risk of infection with meningococcal disease, and so vaccines that can be administered to ...

In this report, we summarize the findings of 10 phase 3 and 4 clinical studies evaluating coadministration of the quadrivalent meningococcal conjugate vaccine ... 5% Hepatitis B 10 mIU/mL ...

GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule.

Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

This success was attributed to both high vaccine effectiveness (direct protection) and to herd immunity (indirect protection). Meningococcal serogroup C conjugate (MCC) vaccines are safe and ...